Laparoscopic right hepatectomy is a technically challenging procedure that requires specific training and expertise. While it provides short-term benefits over open surgery such as reduced blood loss and hospital stay, it remains an innovative procedure that should be introduced cautiously. The requirements to perform a safe laparoscopic right hepatectomy include careful patient selection, specialized equipment, and following a standardized technique. Recommendations are that all liver surgery centers should implement laparoscopic liver resection programs after surgeons receive proper training through fellowships in high-volume centers.
This document discusses several tools for evaluating liver function and predicting postoperative outcomes following hepatic resection. It mentions several studies that found:
- Remnant liver volume/body weight ratio (RLV/BWR) of less than 0.5% was a risk factor for hepatic dysfunction after right trisectionectomy.
- Only a hepatic venous pressure gradient greater than 10 mmHg was a significant risk factor for decompensated cirrhosis after surgery in univariate analysis.
- Indocyanine green retention rate at 15 minutes was significantly higher in patients who died compared to survivors following hepatic resection.
- A posthepatectomy portal vein pressure over 22.5 mmHg was an independent predictor of liver failure and mortality
This document discusses the impact of underlying liver disease on postoperative liver failure after surgery. It covers cirrhosis, chemotherapy-induced liver toxicity, and cholestasis.
For cirrhosis, it recommends patient selection based on Child-Pugh and MELD scores. It suggests limiting major resections to Child A patients without varices or thrombocytopenia. Portal vein embolization can help optimize liver remnant volume.
For chemotherapy-induced toxicity, it warns of increased morbidity from extensive preoperative chemo (>6 cycles) due to sinusoidal injuries. Optimization may include stopping bevacizumab.
For cholestasis, it recommends optimizing patients preoperatively with endoscopic
Conférence du Professeur Philippe Mathurin (Hôpital Universitaire Claure Huriez, Lille, France), Juin 2014. Le "Binge Drinking" est un des enjeux de santé publique majeur dans tous les pays occidentaux. Une augmentation de la mortalité par cirrhose alcoolique est constatée dans les pays où l'alcoolisme chronique et le Binge Drinking sont les plus répandus.
Liver Transplantation with severe steatotic graft and postoperative organ dys...Eric Vibert, MD, PhD
This document summarizes the case of a 54-year-old man who underwent an initial liver transplantation with a graft that was found to have over 50% macrosteatosis and 10% microsteatosis, resulting in severe postoperative organ dysfunction requiring a second liver transplantation. Despite a long postoperative course including 12 weeks in the ICU and pancreatic complications, the patient survived and was asymptomatic with normal liver function tests at a 3-year follow up.
This document discusses the results of liver resection versus liver transplantation for hepatocellular carcinoma. It summarizes various studies comparing outcomes such as overall survival and disease-free survival between the two treatments. The document concludes that liver transplantation provides better long-term and disease-free outcomes overall, though liver resection may be comparable for very small solitary tumors. It also notes that salvage transplantation after resection is not ideal since many patients are ineligible after recurrence. When transplant organ availability is limited, it argues hepatocellular carcinoma patients should not be excluded if their survival benefit from transplantation would be similar to those with end-stage liver disease.
Suppléance hépatique : comment et pour qui ?
Pr Didier Samuel et Pr Saliba Faouzi
Les journées du Centre Hépato-Biliaire - JCHB 2019
Journées de l'hépatologie
Laparoscopic right hepatectomy is a technically challenging procedure that requires specific training and expertise. While it provides short-term benefits over open surgery such as reduced blood loss and hospital stay, it remains an innovative procedure that should be introduced cautiously. The requirements to perform a safe laparoscopic right hepatectomy include careful patient selection, specialized equipment, and following a standardized technique. Recommendations are that all liver surgery centers should implement laparoscopic liver resection programs after surgeons receive proper training through fellowships in high-volume centers.
This document discusses several tools for evaluating liver function and predicting postoperative outcomes following hepatic resection. It mentions several studies that found:
- Remnant liver volume/body weight ratio (RLV/BWR) of less than 0.5% was a risk factor for hepatic dysfunction after right trisectionectomy.
- Only a hepatic venous pressure gradient greater than 10 mmHg was a significant risk factor for decompensated cirrhosis after surgery in univariate analysis.
- Indocyanine green retention rate at 15 minutes was significantly higher in patients who died compared to survivors following hepatic resection.
- A posthepatectomy portal vein pressure over 22.5 mmHg was an independent predictor of liver failure and mortality
This document discusses the impact of underlying liver disease on postoperative liver failure after surgery. It covers cirrhosis, chemotherapy-induced liver toxicity, and cholestasis.
For cirrhosis, it recommends patient selection based on Child-Pugh and MELD scores. It suggests limiting major resections to Child A patients without varices or thrombocytopenia. Portal vein embolization can help optimize liver remnant volume.
For chemotherapy-induced toxicity, it warns of increased morbidity from extensive preoperative chemo (>6 cycles) due to sinusoidal injuries. Optimization may include stopping bevacizumab.
For cholestasis, it recommends optimizing patients preoperatively with endoscopic
Conférence du Professeur Philippe Mathurin (Hôpital Universitaire Claure Huriez, Lille, France), Juin 2014. Le "Binge Drinking" est un des enjeux de santé publique majeur dans tous les pays occidentaux. Une augmentation de la mortalité par cirrhose alcoolique est constatée dans les pays où l'alcoolisme chronique et le Binge Drinking sont les plus répandus.
Liver Transplantation with severe steatotic graft and postoperative organ dys...Eric Vibert, MD, PhD
This document summarizes the case of a 54-year-old man who underwent an initial liver transplantation with a graft that was found to have over 50% macrosteatosis and 10% microsteatosis, resulting in severe postoperative organ dysfunction requiring a second liver transplantation. Despite a long postoperative course including 12 weeks in the ICU and pancreatic complications, the patient survived and was asymptomatic with normal liver function tests at a 3-year follow up.
This document discusses the results of liver resection versus liver transplantation for hepatocellular carcinoma. It summarizes various studies comparing outcomes such as overall survival and disease-free survival between the two treatments. The document concludes that liver transplantation provides better long-term and disease-free outcomes overall, though liver resection may be comparable for very small solitary tumors. It also notes that salvage transplantation after resection is not ideal since many patients are ineligible after recurrence. When transplant organ availability is limited, it argues hepatocellular carcinoma patients should not be excluded if their survival benefit from transplantation would be similar to those with end-stage liver disease.
Suppléance hépatique : comment et pour qui ?
Pr Didier Samuel et Pr Saliba Faouzi
Les journées du Centre Hépato-Biliaire - JCHB 2019
Journées de l'hépatologie
This document discusses predicting postoperative outcomes for patients undergoing surgery for hepatocellular carcinoma (HCC). It finds that acceptable postoperative mortality in cirrhotic patients is less than 5%. Pre-operative parameters like liver stiffness measurement, hepatic venous pressure gradient, and indocyanine green clearance can help predict outcomes. Laparoscopic surgery and modulating portal flow may help improve outcomes compared to open surgery for cirrhotic patients undergoing liver resection. Direct assessment of liver function and parenchyma quality are important to predict postoperative liver decompensation risk, especially for patients with a MELD score greater than 8 undergoing minor hepatectomy.
1) Radiofrequency ablation is recommended as the main ablative therapy for HCC tumors less than 5 cm due to better control of the disease. Ablation and resection may be equivalent for very early and early stage HCC.
2) For HCC less than 5 cm in candidates for surgery, the role of new ablation techniques needs to be defined, tool by tool. Combined treatment (TACE+RF) may help address the difficulty of distant recurrence.
3) DEB-TACE and conventional TACE showed similar efficacy and safety profiles in a randomized controlled trial for intermediate HCC, with less post-procedure pain with DEB-TACE. Optimization of bead size is ongoing.
This document summarizes research on alternatives to cadaveric liver transplantation, including living donor liver transplantation and split liver transplantation. It finds that living donor liver transplantation can provide survival rates similar to cadaveric transplantation for patients with hepatocellular carcinoma, with wait times reduced to 6 months to 1 year. Techniques for living donor liver transplantation have improved over time, with experiences centers achieving lower complication rates through refinements like splenectomy for high portal venous pressure.
Liver transplantation is now feasible for HIV-positive patients with end-stage liver disease or hepatocellular carcinoma. While early outcomes for liver transplant in HIV patients showed lower survival rates compared to HIV-negative patients, outcomes have improved with effective HIV viral suppression using antiretroviral therapy. The development of new, highly effective treatments for hepatitis C have significantly improved post-transplant survival rates for those with HIV/HCV coinfection. Close monitoring of tumor markers is important for HIV-positive liver transplant candidates with hepatocellular carcinoma to prevent drop-off from the waitlist.
The detrimental effects of Donor Specific HLA alloantibodies (DSA) on outcomes following liver organ transplantation have been known for many years.
Liver transplantation is an exception but some evidence has been recently highlighted, showing that DSA could be associated with acute antibody-mediated rejection, chronic rejection, plasma cell hepatitis, anastomotic biliary stricture, NRH, fibrosis progression... The prevalence of preformed donor specific DSA is about 20% and the incidence of de novo DSA is about 10% in Liver transplantation (LT). DSA are associated with several graft diseases, mainly AMR but diagnosis was made on histological features+/-C4d staining. De novo DSA and preformed class II DSA, especially with high MFI, seem to pejoratively influence outcomes after LT. When associated with HCV, DSA worsen fibrosis progression. Thanks to antiviral IFN-free regimen, therapeutic strategies of DSA positivity and/or AMR will not differ from HCV- recipients, but need to be evaluated in prospective studies.
Innovations in HCC surgery allow for more precise evaluation of surgical feasibility and improved surgical techniques. Liver stiffness measurement and tumor biology help determine patient risk and optimal resection approach. Virtual hepatectomy and laparoscopic techniques decrease postoperative liver failure risk compared to open surgery. Emerging tools like fluorescent imaging may help identify additional tumors during surgery and guide resection margins. Continued innovation aims to maximize the benefits of surgery for HCC patients.
This document summarizes information from a presentation on surgery for early-stage hepatocellular carcinoma (HCC). It discusses outcomes of liver resection for HCC tumors under 2 cm, including a 98% rate of complete radiological necrosis. It also examines factors like tumor size and number, presence of satellite nodules or cirrhosis that affect risk of recurrence. Additionally, it evaluates tools like indocyanine green retention at 15 minutes to assess liver functional reserve and risk of post-operative liver failure. The conclusion is that liver resection can cure early HCC when the patient has sufficient liver function and the surgery contains an adequate safety margin.
1. Aggressive HCC requiring wide margins and anatomical resection include satellite nodules, rapid AFP kinetics, and poor differentiation.
2. Minor hepatectomy is feasible for MELD <12 and FibroScan <17-20 kPa, while major hepatectomy requires preoperative portal vein embolization, especially for abnormal liver parenchyma.
3. Surgery may be useful for select BCLC C patients, though adjuvant treatments need further exploration to improve outcomes.
Conférence du Dr. Maximiliano GELLI (Chirurgien hépatique, AP-HP Hôpital Paul Brousse, Villejuif, France) aux Journées de Chirurgie Hépato-Biliaire, juin 2014, Paris.
1) Liver transplantation has generally not proven effective for cholangiocarcinoma except possibly for very small (less than 2 cm) intrahepatic cholangiocarcinoma.
2) The Mayo Clinic protocol of neoadjuvant radiation and chemotherapy followed by liver transplantation for non-resectable perihilar cholangiocarcinoma has significantly improved outcomes compared to standard treatments, though 25% of patients drop out of the protocol.
3) The ongoing TRANSPHIL study aims to determine if the Mayo Clinic protocol provides any benefit compared to surgery alone for resectable perihilar cholangiocarcinoma less than 3 cm by randomizing eligible patients to each treatment.
Liver transplantation vs Resection in cholangiocarcinoma on cirrhosisEric Vibert, MD, PhD
1) Liver transplantation significantly improved overall survival and disease-free survival compared to resection for cirrhotic patients with small intrahepatic cholangiocarcinoma and/or hepatocholangiocarcinoma.
2) Factors associated with better outcomes after liver transplantation included transplantation versus resection, and tumors meeting Milan criteria.
3) The results justify reconsidering liver transplantation and a randomized study of transplantation versus surgery for intrahepatic cholangiocarcinoma and hepatocholangiocarcinoma less than 5 cm.
Portal vein embolization is performed to avoid post-operative liver failure after major hepatectomies for colorectal liver metastases. It allows the future liver remnant to hypertrophy before surgery. Portal vein embolization increases the volume of the future liver remnant by 20-30% within 4 weeks. It also stimulates the growth of colorectal liver metastases, so the interval between embolization and hepatectomy should be kept short. Alternative techniques to portal vein embolization are being explored to prevent post-operative liver failure without accelerating tumor growth.
This study aimed to validate the Baveno VI criteria for screening esophageal varices in patients with compensated chronic liver disease in India. The study found that the Baveno VI criteria, which recommends no screening endoscopy for patients with a liver stiffness measurement under 20 kPa and platelet count over 150,000, identified varices requiring treatment (high risk varices) with 96% sensitivity and 99% negative predictive value. An alternative criteria using MELD score and platelet count identified a similar number of patients who could safely avoid endoscopy. This validation of non-invasive measures could reduce unnecessary endoscopies while still identifying patients requiring treatment or surveillance.
INTRODUCCIÓN AL PATIENT BLOOD MANAGEMENT. Conferencia Inagural. Prof HerreraJosé Antonio García Erce
Curso de actualización en patient blood management. Taller CASTYM (Control Avanzado del Sangrado en Trauma y Cirugía Mayor). 2ª Edición
CURSOS EXTRAORDINARIOS UNIVERSIDAD DE ZARAGOZA. Jaca 2017
1) Retroperitoneal endoscopic necrosectomy and NOTES pancreatic necrosectomy are minimally invasive techniques for treating infected pancreatic necrosis as an alternative to open necrosectomy.
2) The document describes various management techniques for infected pancreatic necrosis including percutaneous drainage, endoscopic approaches, laparoscopic debridement, and retroperitoneal approaches.
3) Case studies demonstrate the use of techniques like transgastric endoscopic necrosectomy, retroperitoneal necrosectomy, and endoscopic cystogastrostomy to treat infected pancreatic necrosis.
Conferencia magistral "20 años de Angioplastia Primaria para el tratamiento del Infarto. Experiencia y evolución de las redes de infarto" del Dr. Petr Widimsky durante la XXV Reunión Anual de la Sección de Hemodinámica y Cardiología Intervencionista (SHCI) de 2014 en Córdoba.
Surgery at the Borderline in HCC patient - EASL Conference - Vienna 2015Eric Vibert, MD, PhD
1) Portal hypertension is not necessarily a contraindication for resection of HCC if the extent of surgery is adapted to the degree of portal hypertension and the location of the tumor in the liver is considered.
2) The size of a HCC tumor is less important than the tumor morphology and patient condition in determining resectability for large HCC tumors.
3) Surgery may be useful for HCC with intrahepatic portal or hepatic vein invasion but is more debatable for invasion into a large portal branch or portal trunk, and neoadjuvant treatments should be developed for these patients.
Lección inaugural: “Patient Blood Management: concepto, componentes e implementación” Prof A. Herrera
“CURSO DE ACTUALIZACIÓN EN PATIENT BLOOD MANAGEMENT”.
Taller CASTYM (Control Avanzado del Sangrado en Trauma y Cirugía Mayor). Tercera Edición
Rivaroxaban versus Warfarina en el tratamiento de la Fibrilación AuricularHospital Guadix
This randomized controlled trial compared the anticoagulant rivaroxaban to warfarin for preventing stroke in patients with nonvalvular atrial fibrillation. Over 14,000 patients were assigned to either rivaroxaban or warfarin. In the primary analysis, rivaroxaban was found to be noninferior to warfarin in preventing strokes and systemic embolisms. Rivaroxaban was also associated with less intracranial hemorrhaging and fatal bleeding than warfarin. Major bleeding events occurred at a similar rate between the two groups. The study provides evidence that rivaroxaban is a noninferior alternative to warfarin for preventing strokes in patients with atrial fib
Présentation du Dr. Revault, médecin Coordinateur du COMEDE au Staff d'Hépatologie (CHU Paul-Brousse, Villejuif, France) - 25 fev 2015.
1. Présentation du Comité pour la santé des exilés
2. Principales caractéristiques des populations accompagnées et soignées
3. Difficultés d'accès aux soins, dispositifs de couverture maladie et droit au séjour pour raison médicale
This document discusses predicting postoperative outcomes for patients undergoing surgery for hepatocellular carcinoma (HCC). It finds that acceptable postoperative mortality in cirrhotic patients is less than 5%. Pre-operative parameters like liver stiffness measurement, hepatic venous pressure gradient, and indocyanine green clearance can help predict outcomes. Laparoscopic surgery and modulating portal flow may help improve outcomes compared to open surgery for cirrhotic patients undergoing liver resection. Direct assessment of liver function and parenchyma quality are important to predict postoperative liver decompensation risk, especially for patients with a MELD score greater than 8 undergoing minor hepatectomy.
1) Radiofrequency ablation is recommended as the main ablative therapy for HCC tumors less than 5 cm due to better control of the disease. Ablation and resection may be equivalent for very early and early stage HCC.
2) For HCC less than 5 cm in candidates for surgery, the role of new ablation techniques needs to be defined, tool by tool. Combined treatment (TACE+RF) may help address the difficulty of distant recurrence.
3) DEB-TACE and conventional TACE showed similar efficacy and safety profiles in a randomized controlled trial for intermediate HCC, with less post-procedure pain with DEB-TACE. Optimization of bead size is ongoing.
This document summarizes research on alternatives to cadaveric liver transplantation, including living donor liver transplantation and split liver transplantation. It finds that living donor liver transplantation can provide survival rates similar to cadaveric transplantation for patients with hepatocellular carcinoma, with wait times reduced to 6 months to 1 year. Techniques for living donor liver transplantation have improved over time, with experiences centers achieving lower complication rates through refinements like splenectomy for high portal venous pressure.
Liver transplantation is now feasible for HIV-positive patients with end-stage liver disease or hepatocellular carcinoma. While early outcomes for liver transplant in HIV patients showed lower survival rates compared to HIV-negative patients, outcomes have improved with effective HIV viral suppression using antiretroviral therapy. The development of new, highly effective treatments for hepatitis C have significantly improved post-transplant survival rates for those with HIV/HCV coinfection. Close monitoring of tumor markers is important for HIV-positive liver transplant candidates with hepatocellular carcinoma to prevent drop-off from the waitlist.
The detrimental effects of Donor Specific HLA alloantibodies (DSA) on outcomes following liver organ transplantation have been known for many years.
Liver transplantation is an exception but some evidence has been recently highlighted, showing that DSA could be associated with acute antibody-mediated rejection, chronic rejection, plasma cell hepatitis, anastomotic biliary stricture, NRH, fibrosis progression... The prevalence of preformed donor specific DSA is about 20% and the incidence of de novo DSA is about 10% in Liver transplantation (LT). DSA are associated with several graft diseases, mainly AMR but diagnosis was made on histological features+/-C4d staining. De novo DSA and preformed class II DSA, especially with high MFI, seem to pejoratively influence outcomes after LT. When associated with HCV, DSA worsen fibrosis progression. Thanks to antiviral IFN-free regimen, therapeutic strategies of DSA positivity and/or AMR will not differ from HCV- recipients, but need to be evaluated in prospective studies.
Innovations in HCC surgery allow for more precise evaluation of surgical feasibility and improved surgical techniques. Liver stiffness measurement and tumor biology help determine patient risk and optimal resection approach. Virtual hepatectomy and laparoscopic techniques decrease postoperative liver failure risk compared to open surgery. Emerging tools like fluorescent imaging may help identify additional tumors during surgery and guide resection margins. Continued innovation aims to maximize the benefits of surgery for HCC patients.
This document summarizes information from a presentation on surgery for early-stage hepatocellular carcinoma (HCC). It discusses outcomes of liver resection for HCC tumors under 2 cm, including a 98% rate of complete radiological necrosis. It also examines factors like tumor size and number, presence of satellite nodules or cirrhosis that affect risk of recurrence. Additionally, it evaluates tools like indocyanine green retention at 15 minutes to assess liver functional reserve and risk of post-operative liver failure. The conclusion is that liver resection can cure early HCC when the patient has sufficient liver function and the surgery contains an adequate safety margin.
1. Aggressive HCC requiring wide margins and anatomical resection include satellite nodules, rapid AFP kinetics, and poor differentiation.
2. Minor hepatectomy is feasible for MELD <12 and FibroScan <17-20 kPa, while major hepatectomy requires preoperative portal vein embolization, especially for abnormal liver parenchyma.
3. Surgery may be useful for select BCLC C patients, though adjuvant treatments need further exploration to improve outcomes.
Conférence du Dr. Maximiliano GELLI (Chirurgien hépatique, AP-HP Hôpital Paul Brousse, Villejuif, France) aux Journées de Chirurgie Hépato-Biliaire, juin 2014, Paris.
1) Liver transplantation has generally not proven effective for cholangiocarcinoma except possibly for very small (less than 2 cm) intrahepatic cholangiocarcinoma.
2) The Mayo Clinic protocol of neoadjuvant radiation and chemotherapy followed by liver transplantation for non-resectable perihilar cholangiocarcinoma has significantly improved outcomes compared to standard treatments, though 25% of patients drop out of the protocol.
3) The ongoing TRANSPHIL study aims to determine if the Mayo Clinic protocol provides any benefit compared to surgery alone for resectable perihilar cholangiocarcinoma less than 3 cm by randomizing eligible patients to each treatment.
Liver transplantation vs Resection in cholangiocarcinoma on cirrhosisEric Vibert, MD, PhD
1) Liver transplantation significantly improved overall survival and disease-free survival compared to resection for cirrhotic patients with small intrahepatic cholangiocarcinoma and/or hepatocholangiocarcinoma.
2) Factors associated with better outcomes after liver transplantation included transplantation versus resection, and tumors meeting Milan criteria.
3) The results justify reconsidering liver transplantation and a randomized study of transplantation versus surgery for intrahepatic cholangiocarcinoma and hepatocholangiocarcinoma less than 5 cm.
Portal vein embolization is performed to avoid post-operative liver failure after major hepatectomies for colorectal liver metastases. It allows the future liver remnant to hypertrophy before surgery. Portal vein embolization increases the volume of the future liver remnant by 20-30% within 4 weeks. It also stimulates the growth of colorectal liver metastases, so the interval between embolization and hepatectomy should be kept short. Alternative techniques to portal vein embolization are being explored to prevent post-operative liver failure without accelerating tumor growth.
This study aimed to validate the Baveno VI criteria for screening esophageal varices in patients with compensated chronic liver disease in India. The study found that the Baveno VI criteria, which recommends no screening endoscopy for patients with a liver stiffness measurement under 20 kPa and platelet count over 150,000, identified varices requiring treatment (high risk varices) with 96% sensitivity and 99% negative predictive value. An alternative criteria using MELD score and platelet count identified a similar number of patients who could safely avoid endoscopy. This validation of non-invasive measures could reduce unnecessary endoscopies while still identifying patients requiring treatment or surveillance.
INTRODUCCIÓN AL PATIENT BLOOD MANAGEMENT. Conferencia Inagural. Prof HerreraJosé Antonio García Erce
Curso de actualización en patient blood management. Taller CASTYM (Control Avanzado del Sangrado en Trauma y Cirugía Mayor). 2ª Edición
CURSOS EXTRAORDINARIOS UNIVERSIDAD DE ZARAGOZA. Jaca 2017
1) Retroperitoneal endoscopic necrosectomy and NOTES pancreatic necrosectomy are minimally invasive techniques for treating infected pancreatic necrosis as an alternative to open necrosectomy.
2) The document describes various management techniques for infected pancreatic necrosis including percutaneous drainage, endoscopic approaches, laparoscopic debridement, and retroperitoneal approaches.
3) Case studies demonstrate the use of techniques like transgastric endoscopic necrosectomy, retroperitoneal necrosectomy, and endoscopic cystogastrostomy to treat infected pancreatic necrosis.
Conferencia magistral "20 años de Angioplastia Primaria para el tratamiento del Infarto. Experiencia y evolución de las redes de infarto" del Dr. Petr Widimsky durante la XXV Reunión Anual de la Sección de Hemodinámica y Cardiología Intervencionista (SHCI) de 2014 en Córdoba.
Surgery at the Borderline in HCC patient - EASL Conference - Vienna 2015Eric Vibert, MD, PhD
1) Portal hypertension is not necessarily a contraindication for resection of HCC if the extent of surgery is adapted to the degree of portal hypertension and the location of the tumor in the liver is considered.
2) The size of a HCC tumor is less important than the tumor morphology and patient condition in determining resectability for large HCC tumors.
3) Surgery may be useful for HCC with intrahepatic portal or hepatic vein invasion but is more debatable for invasion into a large portal branch or portal trunk, and neoadjuvant treatments should be developed for these patients.
Lección inaugural: “Patient Blood Management: concepto, componentes e implementación” Prof A. Herrera
“CURSO DE ACTUALIZACIÓN EN PATIENT BLOOD MANAGEMENT”.
Taller CASTYM (Control Avanzado del Sangrado en Trauma y Cirugía Mayor). Tercera Edición
Rivaroxaban versus Warfarina en el tratamiento de la Fibrilación AuricularHospital Guadix
This randomized controlled trial compared the anticoagulant rivaroxaban to warfarin for preventing stroke in patients with nonvalvular atrial fibrillation. Over 14,000 patients were assigned to either rivaroxaban or warfarin. In the primary analysis, rivaroxaban was found to be noninferior to warfarin in preventing strokes and systemic embolisms. Rivaroxaban was also associated with less intracranial hemorrhaging and fatal bleeding than warfarin. Major bleeding events occurred at a similar rate between the two groups. The study provides evidence that rivaroxaban is a noninferior alternative to warfarin for preventing strokes in patients with atrial fib
Présentation du Dr. Revault, médecin Coordinateur du COMEDE au Staff d'Hépatologie (CHU Paul-Brousse, Villejuif, France) - 25 fev 2015.
1. Présentation du Comité pour la santé des exilés
2. Principales caractéristiques des populations accompagnées et soignées
3. Difficultés d'accès aux soins, dispositifs de couverture maladie et droit au séjour pour raison médicale
Publier en Medecine et Science de la vie : Tirer parti de l'offre de publicat...Mony Claire
Les publications scientifiques se multiplient et évoluent. L'Open Access a pris en 15 ans une véritable ampleur et offre au chercheur de nouvelles possibilités pour valoriser son travail.
Conférence du Dr. Florent ARTRU, Réanimateur (Hôpital Universitaire Paul Brousse, Centre hépato-Biliaire), Juin 2014. Résultats des greffes hépatiques en cas de cirrhose grave.
Conférence du Prof. Gilles Pelletier présentant les règles d'attribution des greffons hépatiques pour les patients souffrant d'un cancer primaire du foie (CHC). Conférence donnée en juin 2014. France.
Les traitements de l'hépatite C chronique en 2014, pour les patients cirrhotiques et transplantés : Nouvelles molécules, Résultats, Traitement selon le génotype, Telaprevir, Boceprevir, Sofosbuvir, Simeprevir, Daclatasvir, Ledipasvir, Ombitasvir, Asunaprevir... Conférence du Dr. Audrey COILLY, Hépatologue à l'Hôpital Paul Brousse (France), aux Journées Hépato-Biliaire (13 Juin 2014, Paris).
Les tests de dépistage rapide de l'Hépatite C : Quel impact sur la prise en charge de nos patients ? Conférence du Dr. Pascal Mélin (Centre Hospitalier de Saint-Dizier, France)
Conférence du Professeur Didier Samuel (Hépatologue, Hôpital Paul Brousse, France). Stratégie thérapeutique pour l'élimination de l'antigène HBs (AgHBs) chez les patients porteurs d'une hépatite B chronique.
Conférence du Pr. Vincent Leroy (Hôpital Universitaire de Grenoble, France), Juin 2014. Prise en charge de l'Hépatite C à l'aide des nouveaux antiviraux Sofosbuvir, Daclatasvir, Siméprévir, en combinaison ou non avec l'Interféron pégylé et la Ribavirine.
Conférence du Dr. Bruno Roche (Hépatologue, Hôpital Paul Brousse, France). Physiopathologie, Facteurs de risque, incidence et prise en charge de la réactivation virale B après négativation du virus.
These slides describe the pathophysiology and the management of patients with liver cirrhosis and portal hypertension. The slides are at the level of post-graduate students
Portal vein thrombosis: scenarios and principles of treatmentDe Gottardi Andrea
This document discusses portal vein thrombosis (PVT), including the scenarios, principles of treatment, and a clinical case example. It begins by outlining Virchow's triad as the underlying causes of venous thrombus formation. It then describes the different scenarios of PVT, including acute (with or without cirrhosis) and chronic PVT. Treatment principles aim to recanalize obstructed veins in acute PVT to prevent complications. Anticoagulation is the mainstay treatment and can achieve recanalization rates of up to 80%, with thrombolysis and surgery as other options. Chronic PVT requires preventing recurrence or extension through treating underlying factors and anticoagulation if indicated. A clinical case demonstrates diagnostic imaging
- Variceal hemorrhage is a common complication of cirrhosis that has a high mortality rate. Approximately half of cirrhosis patients have gastroesophageal varices at diagnosis.
- Risk factors for initial and recurrent variceal hemorrhage include large variceal size, presence of red wale marks, and advanced liver disease. Preventative treatment includes nonselective beta blockers and endoscopic variceal ligation.
- For acute hemorrhage, treatment involves IV fluids, vasoconstrictors like terlipressin, antibiotics, and endoscopic therapy. Recurrent hemorrhage is managed with repeat endoscopy, TIPS, or transplantation. Early recognition and management can reduce
Portal hypertension results from increased resistance to blood flow through the liver and can cause dangerous complications like variceal bleeding and ascites. The most common cause is cirrhosis which scars and narrows vessels in the liver. Initial presentations may be asymptomatic but can include gastroesophageal varices, ascites, and splenomegaly. Prevention and treatment of variceal bleeding involves beta blockers, band ligation, and as a last resort transjugular intrahepatic portosystemic shunt placement. Ascites is treated through dietary sodium restriction, diuretics, and paracentesis while spontaneous bacterial peritonitis requires antibiotics.
Portal hypertension results from increased resistance to blood flow through the liver and can cause dangerous complications like variceal bleeding and ascites. Variceal bleeding is a major cause of mortality in cirrhosis and requires rapid fluid resuscitation and treatment to stop bleeding, often through vasoactive drugs, endoscopic variceal ligation or transjugular intrahepatic portosystemic shunt placement. Ascites develops due to fluid leakage from blood vessels and impaired fluid regulation, and is treated through dietary sodium restriction, diuretics and paracentesis.
This document discusses the management of variceal bleeding, specifically focusing on esophageal and gastric varices. It provides an overview of endoscopic and medical therapies for controlling acute esophageal variceal bleeding such as endoscopic band ligation, sclerotherapy, and pharmacologic therapies like octreotide. For gastric varices, it describes different classification systems and challenges in managing bleeding, noting endoscopic therapies like sclerotherapy, ligation, and glue injection can control acute bleeding but have high rebleeding risks. It emphasizes a multidisciplinary approach is often needed for gastric variceal management.
This document discusses the management of variceal hemorrhage, a lethal complication of cirrhosis. It covers the natural history of varices, including that 7% of patients develop or see variceal growth each year. Large varices, presence of red signs, advanced liver disease, and previous hemorrhage predict the 1-year risk of first hemorrhage, which is 12-15%. The risk of recurrent hemorrhage within 1 year is 60%, with 15-20% mortality per acute bleeding episode. It also discusses methods of risk stratification for portal hypertension and their ability to predict outcomes.
This document discusses liver biopsy indications, techniques, and findings. It notes that liver biopsy is used for diagnosis, assessing prognosis through disease staging, and assisting treatment decisions. The document covers various biopsy methods and findings for abnormal liver tests, cryptogenic cirrhosis, liver transplant evaluation, and focal lesions. It discusses pre-biopsy testing and management of medications, as well as biopsy devices, the procedure, and potential findings. Liver biopsy provides diagnostic and prognostic information to guide clinical management of liver diseases.
Cirrhosis is a dynamic disease with varying prognosis depending on clinical stage. It results from mechanisms leading to necroinflammation and fibrogenesis. Later stages are characterized by portal hypertension, ascites, encephalopathy, and risk of hepatocellular carcinoma. Treatment and prevention of complications, including screening and cause-specific therapies, can improve outcomes for patients with cirrhosis.
Pulmonary embolism is a blood clot that develops in another part of the body and travels to the lungs, obstructing blood flow. Risk factors include older age, cancer, prior history of DVT/PE, and prolonged immobility. Symptoms can include dyspnea, chest pain, and cough, though many cases are asymptomatic. Diagnosis involves tests like CT angiography, ventilation-perfusion scanning, ultrasound, and D-dimer level. Treatment consists of oxygen, anticoagulation with heparin or warfarin, and sometimes thrombolysis for large clots or right heart strain. Long-term anticoagulation aims to prevent future clots.
This document summarizes the treatment of acute variceal bleeding caused by cirrhosis. It discusses the natural history and prognosis of the condition, including that mortality has decreased to around 20% in recent decades. The risks of early rebleeding and 5-day failure are high, with early rebleeding being a predictor of death from variceal bleeding. General management aims to control initial bleeding in around 80% of patients, prevent early rebleeding, infection, and renal failure, as these are risks for mortality.
Primary sclerosing cholangitis is a chronic progressive disease characterized by inflammation and fibrosis of the bile ducts. It has unknown causes but likely involves genetic and immunological factors. The disease varies in progression and can result in complications like end-stage liver disease, portal hypertension, cholangitis, or cholangiocarcinoma. While most patients with primary sclerosing cholangitis have inflammatory bowel disease, only a minority of inflammatory bowel disease patients develop primary sclerosing cholangitis. There are no proven effective treatments, so management focuses on supportive care and transplantation may be considered for complications.
This document discusses the treatment of pulmonary embolism (PE). It outlines the main objectives of PE treatment as preventing death from PE, post-thrombotic syndrome, and recurrent venous thromboembolism with minimal side effects. The main treatment approaches discussed are anticoagulants, thrombolytic therapy, caval interruption, and surgical removal. Specific treatment recommendations are provided for massive, major and minor PE based on the presence of shock, right ventricular dysfunction, or normal right ventricular function.
Guia de Manejo de Hemorragia Digestiva Varicial en Cirroticoslibra_rza
This document provides guidelines for the management of variceal hemorrhage in patients with cirrhosis. It covers recommendations for primary prophylaxis, control of active bleeding, and secondary prophylaxis. For primary prophylaxis, it recommends non-selective beta-blockers or variceal band ligation. For active bleeding, it recommends antibiotics, vasoconstrictors, and band ligation to control bleeding, with balloon tamponade or TIPSS for failed control. It recommends beta-blockers plus band ligation or monotherapy for secondary prophylaxis.
This document summarizes guidelines for the management of upper gastrointestinal bleeding (UGIB). It discusses initial patient assessment and risk stratification, the role of endoscopy within 24 hours, endoscopic findings that predict risk of rebleeding, endoscopic therapies, post-endoscopy management including PPI infusion, and strategies to prevent recurrent bleeding related to causes like H. pylori and NSAID use. Endoscopy is important to determine the source of bleeding and apply therapies when needed to reduce risks of additional bleeding, surgery, and mortality. Post-endoscopy care involves PPI therapy and follow up based on risk level.
Approach to patients with upper gi bleedingRajesh S
This document provides an overview of a seminar on gastrointestinal bleeding. It begins with an introduction and outline. It then covers topics like the anatomy of the GI tract and sources of bleeding. Diagnostic assessments including history, exams, and tests are reviewed. Approaches to resuscitation, classification of shock, and fluid management are outlined. Etiologies of upper and lower GI bleeding like ulcers, varices, and tumors are summarized. Endoscopic and surgical management strategies are also discussed. Risk factors for poor prognosis with GI bleeding are listed. The document concludes with a risk score to predict need for intervention in GI bleeding cases.
Management of critically-ill cirrhotic patientsMahmoud Eid
This document discusses the management of critically ill cirrhotic patients, focusing on those with acute variceal bleeding. Cirrhotic patients are prone to life-threatening complications requiring emergency care. Variceal bleeding remains a leading cause of mortality, though outcomes have improved over time. Management involves fluid resuscitation, blood product administration, antibiotic prophylaxis, vasoactive drugs, and endoscopic therapy all within 6-12 hours of admission. Early use of covered transjugular portosystemic shunt may improve outcomes in high-risk patients.
Kurdistan Boar GEH J Club: PVT From Saudi J Gastroenterology.Shaikhani.
1) The document discusses portal vein thrombosis (PVT), specifically extrahepatic portal vein obstruction (EHPVO). EHPVO is a common cause of portal hypertension and can present from infancy to adulthood.
2) Clinical features depend on whether the PVT is acute or chronic. Acute PVT may cause abdominal pain and infection, while chronic EHPVO often presents with splenomegaly, variceal bleeding, and complications of portal hypertension.
3) Diagnosis involves imaging tests like Doppler ultrasound, CT, or MRI to identify thrombosis, cavernous transformation of the portal vein, and collateral circulation. Treatment depends on whether the PVT is recent or chronic, with recent cases
The document discusses the management of chronic HCV infection for general practitioners. It presents two case histories of patients with chronic HCV infection and asks how the practitioner would proceed. For the first patient, who is treatment experienced, the options are to start DAA treatment, further investigate, or refer to a hepatologist. For the second treatment-naive patient, the options are similar. The document then reviews goals of HCV therapy, endpoints of treatment, benefits of achieving sustained virological response, how to confirm diagnosis and investigate patients, and treatment guidelines for different stages of chronic HCV infection.
Similar to Moreau r betabloquants_non_selectifs_et_cirrhose_hepatique_fev2015 (20)
1. Hypothermic perfusion of the liver during hepatic resection allows for safer total vascular exclusion of over 60 minutes by decreasing metabolic needs and improving hemodynamic tolerance.
2. Hypothermic perfusion can be performed in situ, without dividing the portal triad, or ex situ after dividing the portal triad. Veno-venous bypass is often used to avoid hemodynamic instability during long periods of vascular exclusion.
3. Preliminary experience with 77 cases of hepatic resection using hypothermic perfusion and vascular exclusion showed lower mortality and morbidity compared to standard surgery. Independent predictors of mortality were identified to help patient selection.
This document summarizes research on applications of microtechnology and bioengineering in liver modeling and transplantation. It discusses topics like micropatterning co-cultures, encapsulation, bioartificial and transplantable engineered livers, and using microfluidics and biomaterials for drug screening and disease modeling. Specific techniques covered include differentiating stem cells into liver cells, constructing 3D liver organoids, developing liver-on-chip devices, and applying organoids to study bile acid recycling and treat cholangiopathy. The overall goal is to build functional artificial livers through multidisciplinary approaches like microengineering, stem cell differentiation, organoid development, and organ-chip systems.
More from Centre Hepato-Biliaire / AP-HP Hopital Paul Brousse (20)
Osteoporosis - Definition , Evaluation and Management .pdfJim Jacob Roy
Osteoporosis is an increasing cause of morbidity among the elderly.
In this document , a brief outline of osteoporosis is given , including the risk factors of osteoporosis fractures , the indications for testing bone mineral density and the management of osteoporosis
The skin is the largest organ and its health plays a vital role among the other sense organs. The skin concerns like acne breakout, psoriasis, or anything similar along the lines, finding a qualified and experienced dermatologist becomes paramount.
Clinic ^%[+27633867063*Abortion Pills For Sale In Tembisa Central19various
Clinic ^%[+27633867063*Abortion Pills For Sale In Tembisa Central Clinic ^%[+27633867063*Abortion Pills For Sale In Tembisa CentralClinic ^%[+27633867063*Abortion Pills For Sale In Tembisa CentralClinic ^%[+27633867063*Abortion Pills For Sale In Tembisa CentralClinic ^%[+27633867063*Abortion Pills For Sale In Tembisa Central
Kosmoderma Academy, a leading institution in the field of dermatology and aesthetics, offers comprehensive courses in cosmetology and trichology. Our specialized courses on PRP (Hair), DR+Growth Factor, GFC, and Qr678 are designed to equip practitioners with advanced skills and knowledge to excel in hair restoration and growth treatments.
Travel vaccination in Manchester offers comprehensive immunization services for individuals planning international trips. Expert healthcare providers administer vaccines tailored to your destination, ensuring you stay protected against various diseases. Conveniently located clinics and flexible appointment options make it easy to get the necessary shots before your journey. Stay healthy and travel with confidence by getting vaccinated in Manchester. Visit us: www.nxhealthcare.co.uk
These lecture slides, by Dr Sidra Arshad, offer a simplified look into the mechanisms involved in the regulation of respiration:
Learning objectives:
1. Describe the organisation of respiratory center
2. Describe the nervous control of inspiration and respiratory rhythm
3. Describe the functions of the dorsal and respiratory groups of neurons
4. Describe the influences of the Pneumotaxic and Apneustic centers
5. Explain the role of Hering-Breur inflation reflex in regulation of inspiration
6. Explain the role of central chemoreceptors in regulation of respiration
7. Explain the role of peripheral chemoreceptors in regulation of respiration
8. Explain the regulation of respiration during exercise
9. Integrate the respiratory regulatory mechanisms
10. Describe the Cheyne-Stokes breathing
Study Resources:
1. Chapter 42, Guyton and Hall Textbook of Medical Physiology, 14th edition
2. Chapter 36, Ganong’s Review of Medical Physiology, 26th edition
3. Chapter 13, Human Physiology by Lauralee Sherwood, 9th edition
- Video recording of this lecture in English language: https://youtu.be/Pt1nA32sdHQ
- Video recording of this lecture in Arabic language: https://youtu.be/uFdc9F0rlP0
- Link to download the book free: https://nephrotube.blogspot.com/p/nephrotube-nephrology-books.html
- Link to NephroTube website: www.NephroTube.com
- Link to NephroTube social media accounts: https://nephrotube.blogspot.com/p/join-nephrotube-on-social-media.html
Moreau r betabloquants_non_selectifs_et_cirrhose_hepatique_fev2015
1. Richard Moreau
Inserm U1149, Centre de Recherche sur l’Inflammation (CRI), Paris
UMR S_1149, Université Paris Diderot-Paris 7
DHU UNITY, Service d’Hépatologie, Hôpital Beaujon, APHP, Clichy
Laboratoire d’Excellence Inflamex, ComUE Sorbonne Paris Cité, Paris
Beta-bloquants non-sélectifs :
Indications et contre-indications
dans la cirrhose
Centre Hépato-Biliaire
Hôpital Paul-Brousse
Villejuif, 4 février 2015
2. Dr. Lebrec
We know that ... five
percent of [patients
admitted for variceal
bleeding] develop
hepatorenal syndrome.
Following total
paracentesis,
approximately 10
percent develop
hepatorenal syndrome.
3. AN INCREASE IN PORTAL VENOUS INFLOW SUSTAINS PORTAL HYPERTENSION
Vasodilatation
splanchnique
Distortion de
l’angio-
architechure
hépatique
Veine
porte
Dans la cirrhose, une augmentation du débit
sanguin dans le territoire de la veine porte
maintient l’hypertension portale
Débit sanguin
augmenté
Blanchet et Lebrec. Eur J Clin Invest 1982.
4.
5. Découverte du propranolol comme premier traitement
pharmacologique de l’hypertension portale
Lebrec et al. Lancet 1980;2:180-2.
8. • Prophylaxie pré-primaire
• Prévention d’une première
hémorragie digestive
• Prévention de la récidive
hémorragique
• Effet sur la translocation
bactérienne
• Complications des β-bloquants
Sommaire
9. •All patients with cirrhosis should be
screened for varices at diagnosis
•No indication to use β-blockers to
prevent the formation of varices
•Underlying cause of liver disease should
be treated when possible
•HVPG measurement in the context of
RCTs
•Unmet need: non invasive biomarkers
Pre-primary Prophylaxis
Baveno V Recommendations
de Franchis and Baveno V Faculty. J Hepatol 2010; 53:762-8.
10. • Prophylaxie pré-primaire
• Prévention d’une première
hémorragie digestive
• Prévention de la récidive
hémorragique
• Effet sur la translocation
bactérienne
• Complications des β-bloquants
Sommaire
11. Estimated 1 Year Percentage
Probability of Bleeding
Class A Class B Class C
Red wale
marking Small Large Small Large Small Large
Absent 6 15 10 26 20 42
Mild 8 79 15 33 28 54
Severe 16 34 28 52 44 76
From NIEC. N Engl J Med 1988;319:983-9.
12. •Patients with small varices:
‒ Patients with red wale marks or CP class C
should be treated with nonselective
β-blockers.
‒ Patients without signs of increased risk may
be treated with nonselective β-blockers to
prevent progression of varices and bleeding.
Further studies are required to confirm their
benefit.
Prevention of the First Bleeding Episode
Baveno V Recommendations
de Franchis and Baveno V Faculty. J Hepatol 2010;53:762-8.
13. •Patients with medium-large varices:
‒ Use: either nonselective β-blockers or
endoscopic band ligation (EBL)
‒ Carvedilol is a promising alternative (TBC).
‒ Not recommended: shunt therapy, endoscopic
sclerotherapy, isosorbide mononitrate alone.
‒ Not recommended: nonselective β-blockers in
combination with Isosorbide-5-mononitrate,
spironolactone, or EBL.
Prevention of the First Bleeding Episode
Baveno V Recommendations
de Franchis and Baveno V Faculty. J Hepatol 2010; 53:762-8.
14. •Patients with gastric varices:
‒ No available data
‒ May be treated with
nonselective β-blockers.
Prevention of the First
Bleeding Episode
Baveno V Recommendations
de Franchis and Baveno V Faculty. J Hepatol 2010; 53:762-8.
15. • Prophylaxie pré-primaire
• Prévention d’une première
hémorragie digestive
• Prévention de la récidive
hémorragique
• Effet sur la translocation
bactérienne
• Complications des β-bloquants
Sommaire
16. •Secondary prophylaxis should
start ASAP from day 6 of the index
variceal episode.
•The start time of secondary
prophylaxis should be
documented.
Prevention of Re-bleeding
Baveno V Statement
de Franchis and Baveno V Faculty. J Hepatol 2010; 53:762-8.
17. •Best option: combination of nonselective
β-blockers & band ligation; results in lower
re-bleeding compared to either therapy alone.
•Patients with contra-indications or intolerance
to nonselective β-blockers:
‒ Use EBL
•Patients unable or unwilling to be treated with
EBL:
‒ Use nonselective β-blockers + isosorbide
mononitrate
Prevention of Re-bleeding
Baveno V Recommendations
de Franchis and Baveno V Faculty. J Hepatol 2010; 53:762-8.
18. EBL vs. β-Blockers
+ Isosorbide-5-Mononitrate
in the Prevention of Rebleeding
Rebleeding (%) Mortality (%)
β-Blockers EBL
Iso-5-Mm
β-Blockers EBL
Iso-5-Mm
Villanueva 1
33 49* 26 35
Lo 2
57 38* 13 25
Patch3
44 54 32 23
* Significantly different.
1
N Engl J Med 2001;345:647-55; 2
Gastroenterology 2002;
123:728-34; 3
Gastroenterology 2002;123:1013-9.
First authors
19. Prevention of Recurrent Bleeding
My own Conclusions
β-blockers and band ligation must be
used.
The combination of β-blockers and
nitrates cannot be recommended
but more trials are needed.
20. • Prophylaxie pré-primaire
• Prévention d’une première
hémorragie digestive
• Prévention de la récidive
hémorragique
• Effet sur la translocation
bactérienne
• Complications des β-bloquants
Sommaire
22. • Prophylaxie pré-primaire
• Prévention d’une première
hémorragie digestive
• Prévention de la récidive
hémorragique
• Effet sur la translocation
bactérienne
• Complications des β-bloquants
Sommaire
23. Traitement de l’ascite
Ascite
modérée Ascite
volumineuse
Ascite
réfractaire
• Paracentèses
répétées
+ albumine***
• TIPS
• Transplant. Hép.
Restriction Na
+ Tt Diurétique
progressif
(spironolactone*
+ furosémide**)
Paracentèse
+ Albumine IV***
+ Diurétiques
*Max: 400 mg/j. **Max: 160 mg/j. ***solution à 20 %, 8 g/L d’ascite évacuée.
European Association for the Study of the Liver. J Hepatol 2010;53:397-417.
24. Sestré et al. Hepatology 2010; 52:1017-22.
Poor Prognosis of Patients with Refractory Ascites
25. Sersté et al. Hepatology 2010; 52:1017-22.
Deleterious Effects of β-Blockers on Survival in
Patients with Cirrhosis and Refractory Ascites
26. Variable HR (95% CI) P value
Child-Pugh Score 1.43 (1.28 to 1.60) <0.0001
Refractory ascites category
Diuretic-resistant 1
Diuretic intractable
Serum sodium <125 mmol/L 2.11 (1.34 to 3.34) 0.001
Serum creatinine > 1.5 mg/dL 1.46 (0.92 to 2.29) 0.1
Beta-blocker therapy 2.04 (1.31 to 3.18) 0.0016
Frequency of large-volume
paracentesis
1.42 (1.25 to 1.61) <0.0001
Independent Predictors of Death in
174 Patients with Refractory Ascites
Sersté et al. J Hepatol 2012;57:274-80.
27. Conséquences de la paracentèse
Paracentèse évacuatrice
Ginès et al. Gastroenterology 1996;111:1002-10.
Dysfonction circulatoire (hypotension)
Récidive d’ascite
Hyponatrémie
Syndrome hépatorénal
Décès
28. Sersté et al. J Hepatol 2011;55 :794-9.
Avant arrêt Après arrêt
Fréquence cardiaque pendant la paracentèse,
avant et après arrêt des β-bloquants
29. Sersté et al. J Hepatol 2011;55 :794-9.
Rénine plasmatique pendant la paracentèse,
avant et après arrêt des β-bloquants
Avant arrêt Après arrêt
30. Nonselective β-Blockers Increase Risk of
Death in Patients with Cirrhosis and SBP
Mandorfer et al. Gastroenterology 2014;146:1680-90.
HR=0.75 (0.581-0.968); P=0.027 HR=1.58 (1.098-2.274); P=0.014
31. Nonselective β-Blockers Increase Risk for HRS
and AKI in Patients with Cirrhosis and SBP
Mandorfer et al. Gastroenterology 2014;146:1680-90.
32. Increased Risk of AKI in Patients with Severe Alcoholic
Hepatitis Receiving β-blockers
Sersté et al.
Liver Int 2015;
in press
33. Deleterious Effects of β-Blockers on
Exercise Capacity in 10 Patients with
Portopulmonary Hypertension
Provencher et al. Gastroenterology 2006;130:120-6
On
β-blockers
2 months
after
cessation of
β-blockers
P value
Heart rate
(beats/min)
66 ± 2 81 ± 10 <0.01
6-min walk
test (m)
338 ± 79 417 ± 54 0.01
34. • Dans le cirrhose, les β-bloquants sont
efficaces pour la prévention des hémorragies
digestives.
• Les β-bloquants pourraient diminuer la
translocation bactérienne intestinale.
• Les β-bloquants semblent avoir des effets
délétères chez les malades avec une ascite
réfractaire, les malades avec une SBP ou une
HAA ou une hypertension artérielle
pulmonaire.
Conclusions
My talk will be divided into 5 parts.
- Definitions
- Pathophysiology
- Prognosis
- Management
─ Infection
─ Organ failures
- Prevention
My talk will be divided into 5 parts.
- Definitions
- Pathophysiology
- Prognosis
- Management
─ Infection
─ Organ failures
- Prevention
Refractory ascites is associated with high mortality rate.
We recently studied the predictors of death in a prospective cohort of 174 patients with refractory ascites.
The independent predictors of death were the CP score, the use of beta-blockers, the frequency of LVP and the category of refractory ascites.
As you know, refractory ascites may be diuretic resistant or diuretic intractable. Ascites is diuretic intractable when hyponatremia or renal failure preclude the use of diuretics.
As you can see the fact to have diuretic intractable ascites due to hyponatremia was associated with a poor prognosis.
Finally, please note that the MELD score was not predictor of death in our series. This findings confirms that RA is an exception to MELD.